title: Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of bevacizumab and weekly docetaxel as first- or second-line therapy in patients with metastatic breast cancer (MBC).
  
  
  METHODS
  Twenty-seven MBC patients received i.v. bevacizumab at 10 mg/kg on days 1 and 15 in combination with i.v. docetaxel 35 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Primary end points were to assess toxicity, overall response rate, and progression-free survival. A secondary end point was to assess the relationship between plasma endothelial and cell adhesion markers and clinical outcomes.
  
  
  RESULTS
  One-hundred fifty-eight treatment cycles were administered with a median of six cycles (range 1-15 cycles) per patient. The most common grade 4 toxicities per patient were as follows: 2 (7%)-pulmonary embolus, 1 (4%)-febrile neutropenia, and 1 (4%)-infection; grade 3 toxicities were 4 (15%)-neutropenia, 4 (15%)-fatigue, 2 (7%)-neuropathy, 2 (7%)-athralgias, 2 (7%)-stomatitis, 1 (7%)-pleural effusion, and 1 (4%)-hypertension. The overall response rate was 52% [95% confidence interval (95% CI), 32-71%], median response duration was 6.0 months (95% CI, 4.6-6.5 months), and the median progression-free survival was 7.5 months (95% CI, 6.2-8.3 months). In hypothesis-generating univariate and limited multivariate analyses, E-selectin was statistically significantly associated with response to the combination.
  
  
  CONCLUSIONS
  Bevazicumab in combination with weekly docetaxel is active with acceptable toxicities in MBC. Additional studies evaluating E-selectin as a marker of response to bevacizumab-containing chemotherapy are warranted.
authors.affiliation: Division of Hematology/Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA.
authors.forename: Bhuvaneswari
authors.initials: B
authors.lastname: Ramaswamy
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Elias
authors.forename: Nicole T
authors.initials: NT
authors.lastname: Kelbick
authors.forename: Angela
authors.initials: A
authors.lastname: Dodley
authors.forename: Mark
authors.initials: M
authors.lastname: Morrow
authors.forename: Marsha
authors.initials: M
authors.lastname: Hauger
authors.forename: Joan
authors.initials: J
authors.lastname: Allen
authors.forename: Chris
authors.initials: C
authors.lastname: Rhoades
authors.forename: Kari
authors.initials: K
authors.lastname: Kendra
authors.forename: Helen X
authors.initials: HX
authors.lastname: Chen
authors.forename: S Gail
authors.initials: SG
authors.lastname: Eckhardt
authors.forename: Charles L
authors.initials: CL
authors.lastname: Shapiro
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D000068258:Bevacizumab